Data storage method, device, electronic device and computer readable medium

By using the attribute information and knowledge graph of the drug data, it automatically determines whether the drug data meets the standards, solving the problems of high manual review costs and information omissions, and achieving efficient and accurate review of drug data.

CN113761216BActive Publication Date: 2024-11-15BEIJING JINGDONG TUOXIAN TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110325850.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-03-26
Publication Date
2024-11-15
Estimated Expiration
2041-03-26

AI Technical Summary

Technical Problem

The review of traditional Chinese medicine data relies on manual methods, resulting in high professional labor costs, information omissions and long response time.

Method used

By obtaining the various attribute information of the drug data, the knowledge graph associated with the drug determines the probability set between the drug and the attribute, and judges whether the drug data meets the standards based on the probability set and weights, and performs corresponding processing and storage.

Benefits of technology

It realizes accurate and effective audit of drug data, reduces the cost and time of manual audits, and improves the flexibility and accuracy of audits.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113761216B_ABST
    Figure CN113761216B_ABST
Patent Text Reader

Abstract

The embodiments of the present disclosure disclose a data storage method, device, electronic device, and computer-readable medium. A specific implementation of the method includes: obtaining target drug data, wherein the target drug data includes information on each attribute of the target drug; determining the probability set between the target drug and each attribute based on the knowledge graph associated with the drug, wherein the probability in the probability set characterizes the degree of association between the target drug and the attribute; determining whether the target drug data is up-to-standard data based on the probability set and the weight corresponding to each attribute; in response to the target drug data being up-to-standard data, processing the target drug data to obtain processed drug data; and storing the processed drug data in a drug database. This implementation can accurately and effectively determine whether the target drug data is up-to-standard through the probability set between the target drug and each attribute and the weight corresponding to each attribute.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] Embodiments of the present disclosure relate to the field of computer technology, and in particular to a data storage method, device, electronic device, and computer-readable medium. Background Art

[0002] At present, when each pharmaceutical factory completes the production of each drug, the drug data is often packaged for users to use or for relevant testing agencies to test the various attribute information of the drug. The usual method for determining whether the drug data meets the standards is to manually review the drug data to determine whether the drug data meets the standards. However, manual review of drug data requires a lot of professional manpower costs. Moreover, manual review requires review of the entire amount of drug data, which can easily lead to the omission of some information. In short, manual review of data has limitations in scale, flexibility, data volume, and response time. Summary of the invention

[0003] The content of this disclosure is used to introduce concepts in a brief form, which will be described in detail in the detailed implementation section below. The content of this disclosure is not intended to identify the key features or essential features of the technical solution claimed for protection, nor is it intended to limit the scope of the technical solution claimed for protection.

[0004] Some embodiments of the present disclosure propose data storage methods, devices, equipment, and computer-readable media to solve the technical problems mentioned in the above background technology section.

[0005] In a first aspect, some embodiments of the present disclosure provide a data storage method, the method comprising: acquiring target drug data, wherein the target drug data includes information of various attributes of the target drug; determining a probability set between the target drug and the various attributes based on a knowledge graph associated with the drug, wherein the probability in the probability set represents the degree of association between the target drug and the attributes; determining whether the target drug data is qualified data based on the probability set and the weight corresponding to each attribute; in response to the target drug data being qualified data, processing the target drug data to obtain processed drug data; and storing the processed drug data in a drug database.

[0006] Optionally, the method further includes: using the processed drug data in the drug database as training samples of the knowledge graph, updating the knowledge graph associated with the drug, and obtaining an updated knowledge graph.

[0007] Optionally, the method further includes: in response to the target drug data being substandard data, adding the drug data to a drug data set, wherein the drug data in the drug data set is substandard drug data.

[0008] Optionally, the above-mentioned determination of whether the above-mentioned target drug data is up-to-standard data based on the above-mentioned probability set and the weight corresponding to each of the above-mentioned attributes includes: multiplying the probability of each of the above-mentioned attributes in the above-mentioned probability set and the corresponding weight to generate a multiplied value to obtain a multiplied value set; and determining whether the above-mentioned target drug data is up-to-standard data based on the above-mentioned multiplied value set.

[0009] Optionally, the above-mentioned determining whether the above-mentioned target drug data is qualified data based on the above-mentioned multiplication value set includes: obtaining a predetermined first threshold corresponding to each of the above-mentioned attributes; in response to the multiplication value corresponding to each of the above-mentioned attributes being greater than or equal to the corresponding first threshold, adding each multiplication value in the above-mentioned multiplication value set to obtain the added value; in response to the above-mentioned added value being greater than or equal to the second threshold, determining that the above-mentioned target drug data is qualified data.

[0010] Optionally, in response to the target drug data being up-to-standard data, processing the target drug data to obtain processed drug data, including: in response to the target drug data being up-to-standard data and the attribute information in each attribute of the target drug data being empty, using the drug data stored in the drug database, supplementing the attribute information of the target drug data, and obtaining the target drug data with supplemented attribute information as the processed drug data.

[0011] Optionally, the method further includes: in response to a multiplication value corresponding to an attribute among the attributes being less than a corresponding first threshold, determining the target drug data as substandard data.

[0012] In a second aspect, some embodiments of the present disclosure provide a data storage device, the device comprising: an acquisition unit, configured to acquire target drug data, wherein the target drug data includes information of various attributes of the target drug; a first determination unit, configured to determine a probability set between the target drug and the various attributes based on a knowledge graph associated with the drug, wherein the probability in the probability set represents the degree of association between the target drug and the attributes; a second determination unit, configured to determine whether the target drug data is qualified data based on the probability set and the weight corresponding to each attribute; a processing unit, configured to process the target drug data in response to the target drug data being qualified data to obtain processed drug data; and a storage unit, configured to store the processed drug data in a drug database.

[0013] Optionally, the above-mentioned device also includes: using the above-mentioned processed drug data in the above-mentioned drug database as training samples of the above-mentioned knowledge graph, updating the above-mentioned knowledge graph associated with the drug, and obtaining an updated knowledge graph.

[0014] Optionally, the above-mentioned device also includes: in response to the above-mentioned target drug data being substandard data, adding the above-mentioned drug data to a drug data set, wherein the drug data in the above-mentioned drug data set is substandard drug data.

[0015] Optionally, the second determination unit is further configured to: multiply the probability of each of the above attributes in the above probability set and the corresponding weight to generate a multiplied value to obtain a multiplied value set; and determine whether the above target drug data is qualified data based on the above multiplied value set.

[0016] Optionally, the second determination unit is further configured to: obtain a predetermined first threshold corresponding to each of the above attributes; in response to the multiplication value corresponding to each of the above attributes being greater than or equal to the corresponding first threshold, add each multiplication value in the above multiplication value set to obtain the added value; in response to the above added value being greater than or equal to the second threshold, determine that the above target drug data is qualified data.

[0017] Optionally, the processing unit is further configured to: in response to the target drug data being qualified data and the attribute information in each attribute of the target drug data being empty, use the drug data stored in the drug database to supplement the attribute information of the target drug data, and obtain the target drug data with supplemented attribute information as the processed drug data.

[0018] Optionally, the second determination unit is further configured to: in response to a multiplication value corresponding to an attribute among the above-mentioned attributes being less than a corresponding first threshold value, determine the above-mentioned target drug data as substandard data.

[0019] In a third aspect, some embodiments of the present disclosure provide an electronic device comprising: one or more processors; a storage device having one or more programs stored thereon, wherein when the one or more programs are executed by the one or more processors, the one or more processors implement any method as described in the first aspect.

[0020] In a fourth aspect, some embodiments of the present disclosure provide a computer-readable medium having a computer program stored thereon, wherein when the program is executed by a processor, any method in the first aspect is implemented.

[0021] The above-mentioned various embodiments of the present disclosure have the following beneficial effects: through the data storage method of some embodiments of the present disclosure, the probability set between the target drug and the various attributes and the weight corresponding to each attribute can be used to accurately and effectively determine whether the target drug data meets the standard. Specifically, the drug data needs a lot of professional manpower costs through manual review. Moreover, manual review requires the review of the full amount of drug data, which is easy to cause the omission of some information. In short, the manual review data has limitations in scale, flexibility, data volume and response time. Based on this, the data storage method of some embodiments of the present disclosure can first obtain the target drug data. Among them, the above-mentioned target drug data includes information on various attributes of the target drug. Here, the information on various attributes of the target drug can be used as a data basis for whether the subsequent target drug data meets the standard. Then, according to the knowledge graph associated with the drug, the probability set between the above-mentioned target drug and the above-mentioned attributes is determined. Among them, the probability in the above-mentioned probability set represents the degree of association between the above-mentioned target drug and the above-mentioned attribute. Then, according to the above-mentioned probability set and the weight corresponding to each attribute, it can be accurately and effectively determined whether the above-mentioned target drug data is data that meets the standard. Then, in response to the above-mentioned target drug data being data that meets the standard, the above-mentioned target drug data is processed to obtain the processed drug data. Optionally, the target drug data can be fine-tuned to make the adjusted target drug data more standard and reasonable. Finally, the processed drug data is stored in the drug database. It can be seen that the data storage method can accurately and effectively determine whether the target drug data meets the standard through the probability set between the target drug and each attribute and the weight corresponding to each attribute. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] The above and other features, advantages and aspects of the embodiments of the present disclosure will become more apparent with reference to the following detailed description in conjunction with the accompanying drawings. Throughout the accompanying drawings, the same or similar reference numerals represent the same or similar elements. It should be understood that the drawings are schematic and the originals and elements are not necessarily drawn to scale.

[0023] Figure 1 is a schematic diagram of an application scenario diagram of the data storage method of some embodiments of the present disclosure;

[0024] Figure 2 is a flow chart of some embodiments of the data storage method according to the present disclosure;

[0025] Figure 3 is a schematic diagram of drug data authorization in a data storage method according to some embodiments of the present disclosure;

[0026] Figure 4 are flow charts of other embodiments of the data storage method according to the present disclosure;

[0027] Figure 5 is a schematic diagram of the structure of some embodiments of the data storage device according to the present disclosure;

[0028] Figure 6 It is a schematic diagram of the structure of an electronic device suitable for implementing some embodiments of the present disclosure. DETAILED DESCRIPTION

[0029] Embodiments of the present disclosure will be described in more detail below with reference to the accompanying drawings. Although certain embodiments of the present disclosure are shown in the accompanying drawings, it should be understood that the present disclosure can be implemented in various forms and should not be construed as being limited to the embodiments set forth herein. On the contrary, these embodiments are provided to provide a more thorough and complete understanding of the present disclosure. It should be understood that the drawings and embodiments of the present disclosure are only for exemplary purposes and are not intended to limit the scope of protection of the present disclosure.

[0030] It should also be noted that, for ease of description, only the parts related to the invention are shown in the drawings. In the absence of conflict, the embodiments and features in the embodiments of the present disclosure can be combined with each other.

[0031] It should be noted that the concepts such as "first" and "second" mentioned in the present disclosure are only used to distinguish different devices, modules or units, and are not used to limit the order or interdependence of the functions performed by these devices, modules or units.

[0032] It should be noted that the modifications of "one" and "plurality" mentioned in the present disclosure are illustrative rather than restrictive, and those skilled in the art should understand that unless otherwise clearly indicated in the context, it should be understood as "one or more".

[0033] The names of the messages or information exchanged between multiple devices in the embodiments of the present disclosure are only used for illustrative purposes and are not used to limit the scope of these messages or information.

[0034] The present disclosure will be described in detail below with reference to the accompanying drawings and in conjunction with embodiments.

[0035] Figure 1 It is a schematic diagram of an application scenario diagram of the data storage method in some embodiments of the present disclosure.

[0036] like Figure 1As shown, the electronic device 101 may first obtain the target drug data 102. The target drug data 102 includes information 103 of various attributes of the target drug. In this application scenario, the target drug data 102 may be: "*** drug data". The information 103 of various attributes of the target drug may include: the target drug's treatment disease 1031, the target drug's usage and dosage 1032, the target drug's medication restrictions 1033, the target drug's precautions 1034, the target drug's adverse reactions 1035, and the target drug's applicable population 1036. The above-mentioned treatment disease 1031 may be: "Treatment disease: a series of symptoms caused by colds". The above-mentioned usage and dosage 1032 may be: "Take with boiled water, 3 times a day". The above-mentioned medication restrictions 1033 may be: "None". The above-mentioned precautions 1034 of the target drug may be: "Do not take other antipyretic and analgesic drugs at the same time". The above-mentioned adverse reactions 1035 may be: "Easy to fall asleep". The above-mentioned applicable population 1036 may be: "All people". Then, according to the knowledge graph 106 associated with the drug, the probability set 105 between the target drug and each of the attributes is determined. The probability in the probability set 105 represents the degree of association between the target drug and the attributes. In this application scenario, the probability set 105 includes: probability 1051, probability 1052, probability 1053, probability 1054, probability 1055, and probability 1056. The probability 1051 can be "0.3". The probability 1052 can be "0.15". The probability 1053 can be "0.1". The probability 1054 can be "0.2". The probability 1055 can be "0.15". The probability 1056 can be "0.1". Furthermore, according to the probability set 105 and the weight corresponding to each attribute, it is determined whether the target drug data 102 is qualified data. In this application scenario, the above probability set 104 includes: probability 1041, probability 1042, probability 1043, probability 1044, probability 1045, and probability 1046. The above probability 1041 can be "0.2". The above probability 1042 can be "0.25". The above probability 1043 can be "0.1". The above probability 1044 can be "0.2". The above probability 1045 can be "0.15". The above probability 1046 can be "0.1". Then, in response to the above target drug data 102 being qualified data, the above target drug data 102 is processed to obtain processed drug data 107. The above processed drug data 107 is stored in the drug database 108.

[0037] It should be noted that the electronic device 101 can be hardware or software. When the electronic device is hardware, it can be implemented as a distributed cluster consisting of multiple servers or terminal devices, or it can be implemented as a single server or a single terminal device. When the electronic device is embodied as software, it can be installed in the hardware devices listed above. It can be implemented as multiple software or software modules for providing distributed services, for example, or it can be implemented as a single software or software module. No specific limitation is made here.

[0038] It should be understood that Figure 1 The number of electronic devices in the embodiment is only for illustration. Any number of electronic devices may be provided according to implementation requirements.

[0039] Continue to refer Figure 2 , shows a process 200 of some embodiments of the data storage method according to the present disclosure. The data storage method comprises the following steps:

[0040] Step 201, obtaining target drug data.

[0041] In some embodiments, the execution subject of the data storage method (eg Figure 1 The electronic device 101 shown) can obtain the target drug data through a wired connection or a wireless connection. Among them, the above-mentioned target drug data includes information on various attributes of the target drug. As an example, the information on various attributes of the above-mentioned target drug may include but is not limited to at least one of the following: the treatment disease of the target drug, the usage and dosage of the target drug, the medication restrictions of the target drug, the precautions of the target drug, the adverse reactions of the target drug, and the applicable population of the target drug. The above-mentioned target drug data is data to be determined whether it meets the standards. The above-mentioned target data is authorized data.

[0042] In some embodiments, the execution subject may obtain the drug data in response to receiving a target authorization signal. The target authorization signal may be a signal generated by the drug corresponding to the drug data, when a target operation is performed on a target control. The target control may be included in an authorization prompt box. The authorization prompt box may be displayed on a target terminal device. The target terminal device may be a terminal device logged with an account corresponding to the drug. The terminal device may be a "mobile phone" or a "computer". The target operation may be a "click operation" or a "slide operation". The target control may be a "confirmation button".

[0043] As an example, the authorization prompt box above can be as follows Figure 3As shown. The authorization prompt box may include: a prompt information display part 301 and a control 302. The prompt information display part 301 may be used to display prompt information. The prompt information may be "whether to allow obtaining drug data". The control 302 may be a "confirm button" or a "cancel button".

[0044] It should be noted that the above-mentioned wireless connection methods may include but are not limited to 3G / 4G / 5G connection, WiFi connection, Bluetooth connection, WiMAX connection, Zigbee connection, UWB (ultrawideband) connection, and other wireless connection methods currently known or to be developed in the future.

[0045] Step 202, determining the probability set between the target drug and each of the attributes according to the knowledge graph associated with the drug.

[0046] In some embodiments, the execution subject can determine the probability set between the target drug and each of the attributes based on the knowledge graph associated with the drug. As an example, the serialized text data can be segmented by Jieba word segmentation to obtain a word set. The knowledge graph can be a structured semantic knowledge base for quickly describing the relevant concepts of drugs in the physical world and their interrelationships. The knowledge graph effectively processes, handles and integrates the complex drug data into simple and clear triples of "drugs, relationships between drugs, drugs", and finally aggregates a large amount of knowledge to achieve rapid response and reasoning of knowledge. The nodes in the knowledge graph can be drug entities. As an example, the edges in the knowledge graph can also include the relationship between drugs and diseases that can be treated by drugs.

[0047] As an example, the above execution entity can determine the probability set between the target drug and each of the above attributes through the following formula:

[0048]

[0049] Wherein, h may be the target drug. r may be the target attribute. P may be the histogram of the target attribute value corresponding to the target drug in the target attribute value set corresponding to the first number of drug data. Wherein, the first number of drug data is the data of the target drug in the direction of treatable diseases. Q can be obtained by the following steps: First, determine the histogram distribution of the target attribute value corresponding to each drug in the drug database in the target attribute value set corresponding to the second number of drug data. Then, based on the obtained histogram set corresponding to each drug in the drug database, determine the average histogram in the histogram set corresponding to each drug. Wherein, the above-mentioned first number is less than or equal to the second number. The second number of drug data is the data of drugs in each direction of treatable diseases.

[0050] Step 203, determining whether the target drug data is qualified data based on the probability set and the weight corresponding to each attribute.

[0051] In some embodiments, the execution subject may determine whether the target drug data is up-to-standard data based on the probability set and the weight corresponding to each attribute. The weight of each attribute may be information representing the degree to which the attribute affects the target drug data to be up-to-standard data. The weight of each attribute is pre-set by relevant personnel engaged in the pharmaceutical industry.

[0052] As an example, the execution subject may first multiply each probability in the probability set by the corresponding weight to obtain a multiplication result set. Then, each multiplication result in the multiplication result set is added to obtain a sum value. Finally, in response to the sum value being greater than or equal to a preset threshold, the target drug data is determined to be qualified data.

[0053] In some optional implementations of some embodiments, the determining whether the target drug data is up-to-standard data according to the probability set and the weight corresponding to each attribute may include the following steps:

[0054] In the first step, the probability of each attribute in the above probability set is multiplied by the corresponding weight to generate a multiplied value, thereby obtaining a multiplied value set.

[0055] The second step is to determine whether the target drug data is up-to-standard data based on the multiplied value set. As an example, the execution subject may add up the multiplied values ​​in the multiplied value set to obtain an added value. In response to the added value being greater than or equal to a preset threshold, the target drug data is determined to be up-to-standard data.

[0056] Optionally, the determining whether the target drug data is up-to-standard data according to the multiplied value set may include the following steps:

[0057] In the first step, the execution subject may obtain a predetermined first threshold corresponding to each of the attributes, wherein the first threshold of each of the attributes may be preset.

[0058] In the second step, in response to the multiplication value corresponding to each of the above attributes being greater than or equal to the corresponding first threshold, the execution subject may add the multiplication values ​​in the multiplication value set to obtain the added value. Wherein, relative to the target drug, the multiplication value corresponding to each of the above attributes being greater than or equal to the corresponding first threshold can indicate that the information corresponding to each attribute meets the standard.

[0059] In the third step, in response to the added value being greater than or equal to a second threshold, the execution subject may determine that the target drug data is qualified data, wherein the second threshold is preset.

[0060] Optionally, in response to the multiplication value corresponding to an attribute in the above-mentioned attributes being less than the corresponding first threshold, the above-mentioned execution subject may determine the above-mentioned target drug data as substandard data. Wherein, relative to the target drug, the multiplication value corresponding to each of the above-mentioned attributes being less than the corresponding first threshold may indicate that the information corresponding to each attribute is substandard.

[0061] Step 204, in response to the target drug data being data that meets the standards, the target drug data is processed to obtain processed drug data.

[0062] In some embodiments, the execution entity may process the target drug data in response to the target drug data being data that meets the standards, to obtain processed drug data.

[0063] As an example, in response to the target drug data being up-to-standard data, the execution entity may receive information sent by relevant personnel engaged in drug work to fine-tune attribute information characterizing suspected errors in the target drug data, thereby processing the target drug data to obtain processed drug data.

[0064] In some optional implementations of some embodiments, in response to the target drug data being qualified data and the information of attributes in each attribute of the target drug data being empty, the target drug data is supplemented with attribute information using the drug data stored in the drug database, and the target drug data with supplemented attribute information is obtained as the processed drug data. The information of attributes in each attribute of the target drug data being empty may be that the attribute information of a certain attribute in each attribute of the target drug data is not filled in.

[0065] Step 205, storing the processed drug data in a drug database.

[0066] In some embodiments, the execution entity may store the processed drug data in a drug database.

[0067] In some optional implementations of some embodiments, in response to the target drug data being substandard data, the drug data is added to a drug data set. The drug data in the drug data set is substandard drug data. The drug data set can be used to subsequently determine the reasons why each drug data included therein does not meet the standards.

[0068] The above-mentioned various embodiments of the present disclosure have the following beneficial effects: through the data storage method of some embodiments of the present disclosure, the probability set between the target drug and the various attributes and the weight corresponding to each attribute can be used to accurately and effectively determine whether the target drug data meets the standard. Specifically, the drug data needs a lot of professional manpower costs through manual review. Moreover, manual review requires the review of the full amount of drug data, which is easy to cause the omission of some information. In short, the manual review data has limitations in scale, flexibility, data volume and response time. Based on this, the data storage method of some embodiments of the present disclosure can first obtain the target drug data. Among them, the above-mentioned target drug data includes information on various attributes of the target drug. Here, the information on various attributes of the target drug can be used as a data basis for whether the subsequent target drug data meets the standard. Then, according to the knowledge graph associated with the drug, the probability set between the above-mentioned target drug and the above-mentioned attributes is determined. Among them, the probability in the above-mentioned probability set represents the degree of association between the above-mentioned target drug and the above-mentioned attribute. Then, according to the above-mentioned probability set and the weight corresponding to each attribute, it can be accurately and effectively determined whether the above-mentioned target drug data is data that meets the standard. Then, in response to the above-mentioned target drug data being data that meets the standard, the above-mentioned target drug data is processed to obtain the processed drug data. Optionally, the target drug data can be fine-tuned to make the adjusted target drug data more standard and reasonable. Finally, the processed drug data is stored in the drug database. It can be seen that the data storage method can accurately and effectively determine whether the target drug data meets the standard through the probability set between the target drug and each attribute and the weight corresponding to each attribute.

[0069] Continue to refer Figure 4 , shows a process 400 of another embodiment of the data storage method according to the present disclosure. The data storage method comprises the following steps:

[0070] Step 401, obtaining target drug data.

[0071] Step 402, determining a probability set between the target drug and each of the attributes according to the knowledge graph associated with the drug.

[0072] Step 403, determining whether the target drug data is qualified data based on the probability set and the weight corresponding to each attribute.

[0073] Step 404, in response to the target drug data being data that meets the standards, the target drug data is processed to obtain processed drug data.

[0074] Step 405, storing the processed drug data in the drug database.

[0075] In some embodiments, the specific implementation of steps 201-205 and the technical effects brought about can be referred to Figure 4 The corresponding steps 401-405 in the embodiments are not described in detail here.

[0076] Step 406: Use the processed drug data in the drug database as training samples for the knowledge graph, update the drug-related knowledge graph, and obtain an updated knowledge graph.

[0077] In some embodiments, an execution entity (e.g. Figure 1 The electronic device 101 shown can use the processed drug data in the drug database as training samples for the knowledge graph, update the drug-related knowledge graph, and obtain an updated knowledge graph. It should be noted that by updating the knowledge graph, the updated knowledge graph can be used to more accurately and efficiently determine whether subsequent drug data is up-to-standard data.

[0078] from Figure 4 It can be seen that Figure 2 Compared with the description of some corresponding embodiments, Figure 4 The process 400 of the data storage method in some corresponding embodiments embodies the step of updating the knowledge graph associated with the drug. Therefore, the solutions described in these embodiments can more comprehensively and accurately determine whether the subsequent drug data meets the standards.

[0079] Continue to refer Figure 5 As an implementation of the above methods in the above figures, the present disclosure provides some embodiments of a data storage device, and these device embodiments are Figure 4 Corresponding to the above method embodiments, the device can be specifically applied to various electronic devices.

[0080] like Figure 5As shown, the data storage device 500 of some embodiments includes: an acquisition unit 501, a first determination unit 502, a second determination unit 503, a processing unit 504 and a storage unit 505. Among them, the acquisition unit 501 is configured to acquire target drug data, wherein the target drug data includes information of various attributes of the target drug. The first determination unit 502 is configured to determine the probability set between the target drug and the various attributes according to the knowledge graph associated with the drug, wherein the probability in the probability set characterizes the degree of association between the target drug and the attributes. The second determination unit 503 is configured to determine whether the target drug data is qualified data according to the probability set and the weight corresponding to each attribute. The processing unit 504 is configured to process the target drug data in response to the target drug data being qualified data to obtain the processed drug data. The storage unit 505 is configured to store the processed drug data in the drug database.

[0081] In some optional implementations of some embodiments, the data storage device 500 further includes: a training unit (not shown in the figure). The training unit is configured to: use the processed drug data in the drug database as training samples of the knowledge graph, update the knowledge graph associated with the drug, and obtain an updated knowledge graph.

[0082] In some optional implementations of some embodiments, the data storage device 500 further includes: an adding unit (not shown in the figure). The adding unit is configured to: in response to the target drug data being substandard data, add the drug data to the drug data set, wherein the drug data in the drug data set is substandard drug data.

[0083] In some optional implementations of some embodiments, the second determination unit 503 of the data storage device 500 may be further configured to: multiply the probability of each attribute in the probability set and the corresponding weight to generate a multiplied value, and obtain a multiplied value set; and determine whether the target drug data is qualified data based on the multiplied value set.

[0084] In some optional implementations of some embodiments, the second determination unit 503 of the data storage device 500 may be further configured to: obtain a predetermined first threshold corresponding to each of the above attributes; in response to the multiplication value corresponding to each of the above attributes being greater than or equal to the corresponding first threshold, add each multiplication value in the above multiplication value set to obtain the added value; in response to the above added value being greater than or equal to the second threshold, determine that the above target drug data is qualified data.

[0085] In some optional implementations of some embodiments, the processing unit 504 of the data storage device 500 may be further configured to: in response to the target drug data being qualified data and the attribute information in each attribute of the target drug data being empty, supplement the attribute information of the target drug data using the drug data stored in the drug database, and obtain the target drug data with supplemented attribute information as the processed drug data.

[0086] In some optional implementations of some embodiments, the second determination unit 503 of the data storage device 500 may be further configured to: in response to the existence of a multiplied value corresponding to an attribute in the above-mentioned various attributes being less than the corresponding first threshold, determine the above-mentioned target drug data as substandard data.

[0087] It is understood that the units described in the device 500 are similar to those described in the reference Figure 4 Therefore, the operations, features and beneficial effects described above for the method are also applicable to the device 500 and the units included therein, and will not be described in detail here.

[0088] Reference below Figure 6 , which shows a structural schematic diagram of an electronic device 600 suitable for implementing some embodiments of the present disclosure. Figure 6 The electronic device shown is only an example and should not bring any limitation to the functions and scope of use of the embodiments of the present disclosure.

[0089] like Figure 6 As shown, the electronic device 600 may include a processing device (e.g., a central processing unit, a graphics processing unit, etc.) 601, which can perform various appropriate actions and processes according to a program stored in a read-only memory (ROM) 602 or a program loaded from a storage device 608 into a random access memory (RAM) 603. In the RAM 603, various programs and data required for the operation of the electronic device 600 are also stored. The processing device 601, the ROM 602, and the RAM 603 are connected to each other via a bus 604. An input / output (I / O) interface 605 is also connected to the bus 604.

[0090] Typically, the following devices may be connected to the I / O interface 605: an input device 606 including, for example, a touch screen, a touch pad, a keyboard, a mouse, a camera, a microphone, an accelerometer, a gyroscope, etc.; an output device 607 including, for example, a liquid crystal display (LCD), a speaker, a vibrator, etc.; a storage device 608 including, for example, a magnetic tape, a hard disk, etc.; and a communication device 609. The communication device 609 may allow the electronic device 600 to communicate with other devices wirelessly or by wire to exchange data. Although Figure 6The electronic device 600 is shown with various devices, but it should be understood that it is not required to implement or possess all the devices shown. More or fewer devices may be implemented or possessed instead. Figure 6 Each block shown in the figure may represent one device, or may represent multiple devices as required.

[0091] In particular, according to some embodiments of the present disclosure, the process described above with reference to the flowchart can be implemented as a computer software program. For example, some embodiments of the present disclosure include a computer program product, which includes a computer program carried on a computer-readable medium, and the computer program includes a program code for executing the method shown in the flowchart. In some such embodiments, the computer program can be downloaded and installed from the network through the communication device 609, or installed from the storage device 608, or installed from the ROM 602. When the computer program is executed by the processing device 601, the above-mentioned functions defined in the method of some embodiments of the present disclosure are executed.

[0092] It should be noted that the computer-readable medium in some embodiments of the present disclosure may be a computer-readable signal medium or a computer-readable storage medium or any combination of the two. The computer-readable storage medium may be, for example, but not limited to, an electrical, magnetic, optical, electromagnetic, infrared, or semiconductor system, device or device, or any combination of the above. More specific examples of computer-readable storage media may include, but are not limited to: an electrical connection with one or more wires, a portable computer disk, a hard disk, a random access memory (RAM), a read-only memory (ROM), an erasable programmable read-only memory (EPROM or flash memory), an optical fiber, a portable compact disk read-only memory (CD-ROM), an optical storage device, a magnetic storage device, or any suitable combination of the above. In some embodiments of the present disclosure, the computer-readable storage medium may be any tangible medium containing or storing a program that can be used by or in combination with an instruction execution system, device or device. In some embodiments of the present disclosure, the computer-readable signal medium may include a data signal propagated in a baseband or as part of a carrier wave, in which a computer-readable program code is carried. This propagated data signal may take a variety of forms, including but not limited to electromagnetic signals, optical signals, or any suitable combination of the above. The computer readable signal medium may also be any computer readable medium other than a computer readable storage medium, which may send, propagate or transmit a program for use by or in conjunction with an instruction execution system, apparatus or device. The program code contained on the computer readable medium may be transmitted using any suitable medium, including but not limited to: wires, optical cables, RF (radio frequency), etc., or any suitable combination of the above.

[0093] In some embodiments, the client and the server may communicate using any currently known or future developed network protocol such as HTTP (HyperText Transfer Protocol), and may be interconnected with any form or medium of digital data communication (e.g., a communication network). Examples of communication networks include a local area network ("LAN"), a wide area network ("WAN"), an internet (e.g., the Internet), and a peer-to-peer network (e.g., an ad hoc peer-to-peer network), as well as any currently known or future developed network.

[0094] The computer-readable medium may be included in the device; or it may exist independently without being installed in the electronic device. The computer-readable medium carries one or more programs. When the one or more programs are executed by the electronic device, the electronic device: obtains target drug data, wherein the target drug data includes information of various attributes of the target drug; determines the probability set between the target drug and each of the attributes according to the knowledge graph associated with the drug, wherein the probability in the probability set represents the degree of association between the target drug and the attributes; determines whether the target drug data is qualified data according to the probability set and the weight corresponding to each attribute; in response to the target drug data being qualified data, processes the target drug data to obtain processed drug data; and stores the processed drug data in a drug database.

[0095] Computer program code for performing the operations of some embodiments of the present disclosure may be written in one or more programming languages ​​or a combination thereof, including object-oriented programming languages ​​such as Java, Smalltalk, C++, and conventional procedural programming languages ​​such as "C" or similar programming languages. The program code may be executed entirely on the user's computer, partially on the user's computer, as a separate software package, partially on the user's computer and partially on a remote computer, or entirely on a remote computer or server. In cases involving a remote computer, the remote computer may be connected to the user's computer via any type of network, including a local area network (LAN) or a wide area network (WAN), or may be connected to an external computer (e.g., via the Internet using an Internet service provider).

[0096] The flow chart and block diagram in the accompanying drawings illustrate the possible architecture, function and operation of the system, method and computer program product according to various embodiments of the present disclosure. In this regard, each square box in the flow chart or block diagram can represent a module, a program segment or a part of a code, and the module, the program segment or a part of the code contains one or more executable instructions for realizing the specified logical function. It should also be noted that in some implementations as replacements, the functions marked in the square box can also occur in a sequence different from that marked in the accompanying drawings. For example, two square boxes represented in succession can actually be executed substantially in parallel, and they can sometimes be executed in the opposite order, depending on the functions involved. It should also be noted that each square box in the block diagram and / or flow chart, and the combination of the square boxes in the block diagram and / or flow chart can be implemented with a dedicated hardware-based system that performs a specified function or operation, or can be implemented with a combination of dedicated hardware and computer instructions.

[0097] The units described in some embodiments of the present disclosure may be implemented by software or by hardware. The described units may also be provided in a processor, for example, may be described as: a processor comprising: an acquisition unit, a first determination unit, a second determination unit, a processing unit, and a storage unit. The names of these units do not, in certain cases, constitute limitations on the units themselves, for example, a storage unit may also be described as "a unit for storing the above-mentioned processed drug data in a drug database".

[0098] The functions described above herein may be performed at least in part by one or more hardware logic components. For example, without limitation, exemplary types of hardware logic components that may be used include: field programmable gate arrays (FPGAs), application specific integrated circuits (ASICs), application specific standard products (ASSPs), systems on chips (SOCs), complex programmable logic devices (CPLDs), and the like.

[0099] The above descriptions are only some preferred embodiments of the present disclosure and an explanation of the technical principles used. Those skilled in the art should understand that the scope of the invention involved in the embodiments of the present disclosure is not limited to the technical solutions formed by a specific combination of the above-mentioned technical features, but should also cover other technical solutions formed by any combination of the above-mentioned technical features or their equivalent features without departing from the above-mentioned inventive concept. For example, the above-mentioned features are replaced with the technical features with similar functions disclosed in the embodiments of the present disclosure (but not limited to) and the technical solutions formed.

Claims

1. A data storage method, comprising: Acquire target drug data, wherein the target drug data includes information on various attributes of the target drug; According to the knowledge graph associated with the drug, a probability set between the target drug and each of the attributes is determined, wherein the probability in the probability set represents the degree of association between the target drug and the attribute, The probability set between the target drug and each attribute is determined by the following formula: Wherein, h is the target drug, r is the target attribute, P is the histogram of the target attribute value corresponding to the target drug in the target attribute value set corresponding to the first number of drug data, the first number of drug data is the data of the target drug in the direction of the treatable disease, and Q is obtained by the following steps: determining the histogram distribution of the target attribute value corresponding to each drug in the drug database in the target attribute value set corresponding to the second number of drug data; according to the histogram set corresponding to each drug in the drug database, determining the average histogram in the histogram set corresponding to each drug, wherein the first number is less than or equal to the second number, and the second number of drug data is the data of drugs in each treatable disease direction; Determining whether the target drug data is up-to-standard data according to the probability set and the weight corresponding to each attribute; In response to the target drug data being data that meets the standard, processing the target drug data to obtain processed drug data; The processed drug data is stored in a drug database.

2. The method according to claim 1, wherein: The method further comprises: The processed drug data in the drug database is used as a training sample of the knowledge graph, and the knowledge graph associated with the drug is updated to obtain an updated knowledge graph.

3. The method according to claim 1, wherein: The method further comprises: In response to the target drug data being data that does not meet the standards, the drug data is added to a drug data set, wherein the drug data in the drug data set is drug data that does not meet the standards.

4. The method according to claim 1, wherein: The step of determining whether the target drug data is up-to-standard data according to the probability set and the weight corresponding to each attribute includes: Multiplying the probability of each attribute in the probability set and the corresponding weight to generate a multiplied value, thereby obtaining a multiplied value set; According to the multiplied value set, it is determined whether the target drug data is data that meets the standards.

5. The method according to claim 4, wherein: The step of determining whether the target drug data is up-to-standard data according to the multiplied value set includes: Obtaining a predetermined first threshold corresponding to each attribute; In response to the multiplication value corresponding to each attribute being greater than or equal to the corresponding first threshold, adding each multiplication value in the multiplication value set to obtain an added value; In response to the added value being greater than or equal to a second threshold, the target drug data is determined to be qualified data.

6. The method according to claim 1, wherein: In response to the target drug data being data that meets the standard, processing the target drug data to obtain processed drug data includes: In response to the target drug data being qualified data and the attribute information in each attribute of the target drug data being empty, the attribute information of the target drug data is supplemented using the drug data stored in the drug database, and the target drug data with supplemented attribute information is obtained as the processed drug data.

7. The method according to claim 5, wherein: The method further comprises: In response to the multiplication value corresponding to an attribute among the attributes being less than the corresponding first threshold, the target drug data is determined as substandard data.

8. A data storage device, comprising: an acquisition unit, configured to acquire target drug data, wherein the target drug data includes information of various attributes of the target drug; The first determination unit is configured to determine a probability set between the target drug and each attribute according to a knowledge graph associated with the drug, wherein the probability in the probability set represents the degree of association between the target drug and the attribute, and the probability set between the target drug and each attribute is determined by the following formula: Wherein, h is the target drug, r is the target attribute, P is the histogram of the target attribute value corresponding to the target drug in the target attribute value set corresponding to the first number of drug data, the first number of drug data is the data of the target drug in the direction of the treatable disease, and Q is obtained by the following steps: determining the histogram distribution of the target attribute value corresponding to each drug in the drug database in the target attribute value set corresponding to the second number of drug data; according to the histogram set corresponding to each drug in the drug database, determining the average histogram in the histogram set corresponding to each drug, wherein the first number is less than or equal to the second number, and the second number of drug data is the data of drugs in each treatable disease direction; A second determination unit is configured to determine whether the target drug data is qualified data according to the probability set and the weight corresponding to each attribute; a processing unit configured to, in response to the target drug data being data that meets the standard, process the target drug data to obtain processed drug data; The storage unit is configured to store the processed drug data in a drug database.

9. An electronic device, comprising: one or more processors; A storage device for storing one or more programs; When the one or more programs are executed by the one or more processors, the one or more processors are enabled to implement the method according to any one of claims 1 to 7.

10. A computer readable medium having a computer program stored thereon, wherein: When the program is executed by a processor, the method according to any one of claims 1 to 7 is implemented.